According to the latest report by IMARC Group "Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The global digital dose inhaler market reached a value of US$ 2.49 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.85 Billion by 2027, exhibiting at a CAGR of 15.1% during 2022-2027. Digital dose inhalers are used by patients who have asthma and chronic obstructive pulmonary disease (COPD). They have sensors that track the time of medication administration and offer a low-dose warning indicator. Besides this, they have large display screens for easy accessibility and understanding by varied patients. As they are integrated with advanced technology to enable the automatic transfer of data, they are gaining immense traction across the globe. Request for a free sample copy of this report: https://www.imarcgroup.com/digital-dose-inhaler-market/requestsample Market Trends: There is currently a growing prevalence of chronic respiratory diseases (CRDs), such as lung disorders, bronchial asthma, and pulmonary hypertension (PH), which can be accredited to rising pollution levels and occupational dust exposure.This represents one of the key factors positively influencing the demand for digital dose inhalers around the world. Besides this, governing agencies of several countries and non-governmental organizations (NGOs) are spreading awareness about CRDs and available treatments. This is strengthening the growth of the market. The market is further propelled by the introduction of capsule-based and disposable dry powder inhaler (DPI) devices. Breakup by Type:
- Branded Medication
- Generics Medication
- Metered Dose Inhaler
- Dry Powder Inhaler
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
- 3M Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Limited
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Lupin Limited
- Novartis AG
- OPKO Health Inc.
- Propeller Health (ResMed)
- Sensirion AG Switzerland
- Teva Pharmaceutical Industries Ltd.